Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: unsettled (13), unanswered (8), uncertain (37), vague (3), fluid (477)

Papers Trust Board - 30 January 2020

Description: Date Time Location Chair Apologies Agenda Trust Board – Open Session 30/01/2020 9:00 - 11:45 Conference Room, Heartbeat
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2020/Papers-Trust-Board-30-January-2020.pdf

Handling concerns and complaints policy

Description: Handling Complaints Policy, Version 13.0 Trust reference PET003 Version number 13.0 Description Policy to explain how University Hospital
Url: /Media/UHS-website-2019/Docs/Policies/Handling-concerns-and-complaints-policy.pdf

Health and safety policy

Description: Health and Safety Policy Date Issued: 21/11/18 Review Date: 21/11/21 Document Type: Policy Version: 10.0 Contents
Url: /Media/UHS-website-2019/Docs/Policies/Health-and-safety-policy.pdf

BEACON protocol v8.0 07Mar2023 signed

Description: A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

Clinical law updates

Description: On these pages I discuss the clinical law and the common law relating to information disclosure.
Url: /HealthProfessionals/Clinical-law-updates/Clinicallawupdates.aspx

Papers Trust Board 28 March 2019

Description: Agenda Group Name: Date of Meeting: Venue: Time: Apologies to: Trust Board – Open Session 28 March 2019 Conference Room, Heartb
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2019/Papers-Trust-Board-28-March-2019.pdf

Tisacel-Cytarabine (500)-Etoposide (150)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL – CYTARABINE (500) – ETOPOSIDE (150) Regimen This regimen will only be av
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cytarabine-500-Etoposide-150.pdf

Tisacel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL– CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) Regimen This regimen
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cyclophosphamide-500-Fludarabine-30-Ver1.pdf

Brexucel - Cyclophosphamide (900) - Fludarabine (25)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – BREXUCEL – CYCLOPHOSPHAMIDE (900) – FLUDARABINE (25) This regimen will o
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Brexucel-Cyclophosphamide-900-Fludarabine-25.pdf

Tisacel -Cyclophosphamide (250)-Fludarabine (25)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DLBCL/ FL – TISACEL – FLUDARABINE (25) – CYCLOPHOSPHAMIDE (250) Regimen This
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Tisacel-Cyclophosphamide-250-Fludarabine-25.pdf

1 to 10 of 29

Previous 1 2 3 Next